Emerging genetic biomarkers in lung adenocarcinoma
© The Author(s) 2022..
Comprehensive genomic profiling is a next-generation sequencing approach used to detect several known and emerging genomic alterations. Many genomic variants detected by comprehensive genomic profiling have become recognized as significant cancer biomarkers, leading to the development of major clinical trials. Lung adenocarcinoma has become one of the most targeted cancers for genomic profiling with a series of actionable mutations such as EGFR, KRAS, HER2, BRAF, FGFR, MET, ALK, and many others. The importance of these mutations lies in establishing targeted therapies that significantly change the outcome in lung adenocarcinoma besides the prognostic value of some mutations. This review sheds light on the development of the comprehensive genomic profiling field, mainly lung adenocarcinoma, and discusses the role of a group of mutations in this disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
SAGE open medicine - 10(2022) vom: 01., Seite 20503121221132352 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Barbar, Jawad [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Actionable mutations |
|---|
| Anmerkungen: |
Date Revised 21.07.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1177/20503121221132352 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347920489 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347920489 | ||
| 003 | DE-627 | ||
| 005 | 20231226034955.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/20503121221132352 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1159.xml |
| 035 | |a (DE-627)NLM347920489 | ||
| 035 | |a (NLM)36277445 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barbar, Jawad |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Emerging genetic biomarkers in lung adenocarcinoma |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.07.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2022. | ||
| 520 | |a Comprehensive genomic profiling is a next-generation sequencing approach used to detect several known and emerging genomic alterations. Many genomic variants detected by comprehensive genomic profiling have become recognized as significant cancer biomarkers, leading to the development of major clinical trials. Lung adenocarcinoma has become one of the most targeted cancers for genomic profiling with a series of actionable mutations such as EGFR, KRAS, HER2, BRAF, FGFR, MET, ALK, and many others. The importance of these mutations lies in establishing targeted therapies that significantly change the outcome in lung adenocarcinoma besides the prognostic value of some mutations. This review sheds light on the development of the comprehensive genomic profiling field, mainly lung adenocarcinoma, and discusses the role of a group of mutations in this disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Comprehensive genomic profiling | |
| 650 | 4 | |a actionable mutations | |
| 650 | 4 | |a lung cancer | |
| 650 | 4 | |a next-generation sequencing | |
| 650 | 4 | |a targeted therapy | |
| 700 | 1 | |a Armach, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Hodroj, Mohammad Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Assi, Sahar |e verfasserin |4 aut | |
| 700 | 1 | |a El Nakib, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Chamseddine, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Assi, Hazem I |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t SAGE open medicine |d 2013 |g 10(2022) vom: 01., Seite 20503121221132352 |w (DE-627)NLM241487935 |x 2050-3121 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g day:01 |g pages:20503121221132352 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/20503121221132352 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2022 |b 01 |h 20503121221132352 | ||